Twenty Years On – What Do We Really Know About Ewing Sarcoma And What Is The Path Forward?

摘要: Ewing sarcoma (ES) is a highly aggressive bone and soft-tissue tumor with peak incidence among adolescents young adults. Despite advances in local control systemic chemotherapy, metastatic relapse after an initial clinical remission remains significant problem. In addition, metastasis at the time of presentation or continues to be leading cause death for patients diagnosed ES. Since discovery pathognomonic EWS-FLI1 fusion gene more than 20 years ago, much about molecular cellular biology ES pathogenesis has been learned. recent exploitation stem cell developmental provided key insights into origins role epigenetic deregulation initiation maintenance. Nevertheless, mechanisms that drive remain largely unknown. These gaps our knowledge continue hamper development novel therapeutic strategies may improve outcomes relapsed disease. this article we review current status research, highlighting areas investigation consider have greatest potential yield findings will translate clinically advances.